JUNS (Jupiter Neurosciences) Research & Development: $2.03 Mil (TTM As of Mar. 2026)


JUNS Jupiter Neurosciences Inc JUNS
4 GF Score
Price $0.28
! 6 Warning Signs
View Full Analysis

What is Jupiter Neurosciences Research & Development?

Jupiter Neurosciences JUNS +18.22% 4 Research & Development is $2.03 Mil as of Mar. 2026. GuruFocus rates JUNS with a GF Score™ of 4/100. The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Jupiter Neurosciences's Research & Development for the three months ended in Mar. 2026 was $0.41 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $2.03 Mil.

Jupiter Neurosciences  (NAS:JUNS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Jupiter Neurosciences Research & Development Related Terms

Jupiter Neurosciences Research & Development Historical Data

* Premium members only.

The historical data trend for Jupiter Neurosciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jupiter Neurosciences Research & Development Chart

Jupiter Neurosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 1.45 0.94 0.96 0.49 2.09

Jupiter Neurosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.76 0.82 0.04 0.41
JUNS
4GF Score
Jupiter Neurosciences Inc JUNS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jupiter Neurosciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $2.03 Mil mean?
Jupiter Neurosciences (JUNS) has a Research & Development of $2.03 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Jupiter Neurosciences and its competitors.
Is Jupiter Neurosciences' Research & Development too high?
Jupiter Neurosciences' current Research & Development is $2.03 Mil. Overall, Jupiter Neurosciences has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Jupiter Neurosciences' Research & Development compare to APRE and KAPA?
Jupiter Neurosciences' Research & Development of $2.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Jupiter Neurosciences and its competitors. Jupiter Neurosciences's current Research & Development is $2.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jupiter Neurosciences stock overvalued right now?
Jupiter Neurosciences (JUNS) has a current Research & Development of $2.03 Mil. The current Research & Development is $2.03 Mil. Jupiter Neurosciences' overall GF Score™ is 4/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Jupiter Neurosciences (JUNS), the current Research & Development is $2.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jupiter Neurosciences Business Description

Address 1001 North US Highway 1, Suite 504, Jupiter, FL, USA, 33477
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
4GF Score

Get the complete analysis for JUNS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price